News About: Pharm. Industry
Leading group of Baraclude generics, topped by Bukwang PharmAmong the 62 generics entered in the market of ‘Baraclude,’ a drug expired in patent on the 10th of October, the leading group has been clarified.
According to the UBIST’s outp...
|
Exclusive right in 8 years? It is mutant the Patent Linkage System created
Some domestic pharmaceutical companies has acquired the exclusive sales right of Januvia generics, the antidiabetic treatment which can be launched in 8 years after the year of 2023.
This is because the Januvia’s sal...
‘Cold wave’ of staff reduction in the pharmaceutical industry, having controversy for one-sided discharges
Staff reduction has spread in the pharmaceutical industry.
The layoff movement has been sensed among Korean branches of multinational pharmaceutical company. In particular, it expects controversy as some of them are ...
“Innovative pharmaceutical companies led pharmaceutical results in 2015”
While the growth of the pharmaceutical industry has stood out, innovative pharmaceutical companies were observed to contribute to the industry to draw results.
In addition, the total sales of the 20 innovative pharma...
Zuellig Pharma Korea, “We will help Korean pharmaceuticals to expand foreign markets”Zuellig Pharma Korea announced a position to provide help for innovative pharmaceutical products developed by domestic pharmaceutical companies to enter foreign markets.
In fac...
|
A series of pharmaceutical companies deciding free issue of new shares, spreading shareholder-friendly policy
The dividend payment season has come. Like the last year, pharmaceutical companies have the shareholder-friendly policy, which set the profit-sharing of shareholders as the key value.
In particular, as the number of ...
Average annual growth rate of pharmaceutical manufacturing is 4.98% in 10 years
For the past 10 years, the average annual growth rate of pharmaceutical manufacturing volume was observed to be 4.98%. Although the average annual growth rate of imports was 7.59%, the one of exports was 13.4%, which ...
Chong Kun Dang announces domestic exclusive sales agreement of lupus treatmentOn the 14th, Chong Kun Dang(CEO Young-joo Kim) announced the domestic exclusive sales agreement of ‘IFN-K(interferenon-α-kinoid), a systemic lupus erythematosus(hereinafter refe...
|
‘Velcade Inj,’ soon to be expired in patent, attracts interests of 3 companies, such as Chong Kun Dang
Expiring on the 28th, the patent of ‘Velcade Inj(generic name: bortezomib),’ a Janssen Korea’s multiple myeloma treatment, has attracted attention of domestic pharmaceutical companies.
According to the Ministry of Fo...
Will Baraclude generics surprise the market next year?
Will Baraclude generics, such as Dong-A ST’s Baracle and Hanmi Pharm’s Entecavir Tab, overcome the stronghold of Baraclude next year?
According to the industry concerned on the 15th, large hospitals, such as Seoul Na...
